Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.

Chong Kun Dang Pharm (CKD Pharm) has presented data on their c-Met-targeting antibody-drug conjugate (ADC) CKD-703 for the treatment of solid tumors. CKD-703 was designed based on site-specific conjugation, with a stable and homogeneous drug-antibody ratio profile.

Researchers from Axcynsis Therapeutics Pte. Ltd. presented the development and preclinical characterization of AT-2604, a novel antibody-drug conjugate (ADC) targeting the placental alkaline phosphatases, ALPP and ALPPL2.

Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs.